Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches

James C Marsh, Benjamin T Gielda, Arnold M Herskovic, Ross A Abrams, James C Marsh, Benjamin T Gielda, Arnold M Herskovic, Ross A Abrams

Abstract

Whole brain radiotherapy (WBRT) for the palliation of metastases, or as prophylaxis to prevent intracranial metastases, can be associated with subacute and late decline in memory and other cognitive functions. Moreover, these changes are often increased in both frequency and severity when cranial irradiation is combined with the use of systemic or intrathecal chemotherapy. Approaches to preventing or reducing this toxicity include the use of stereotactic radiosurgery (SRS) instead of WBRT; dose reduction for PCI; exclusion of the limbic circuit, hippocampal formation, and/or neural stem cell regions of the brain during radiotherapy; avoidance of intrathecal and/or systemic chemotherapy during radiotherapy; the use of high-dose, systemic chemotherapy in lieu of WBRT. This review discusses these concepts in detail as well as providing both neuroanatomic and radiobiologic background relevant to these issues.

Figures

Figure 1
Figure 1
Hippocampus and Limbic Circuit (http://www.thebrain.mcgill.ca/).
Figure 2
Figure 2
Axial 3D rendering of the hippocampus (purple) and limbic circuit (yellow) contours.
Figure 3
Figure 3
MRI images demonstrating location of (a) hippocampus, and (b) fornix and cingulate gyrus (Marsh et al. [121]). (a) Hippocampus contoured on coronal, sagittal, and axial MRI images. (b) Axial MRI demonstrating location of fornix and cingulated gyrus (anterior and posterior).
Figure 4
Figure 4
Neural stem cell (NSC) regions of the brain (Barani et al. [143]).

References

    1. Ewend MG, Elbabaa S, Carey LA. Current treatment paradigms for the management of patients with brain metastases. Neurosurgery. 2005;57(5):S66–S77.
    1. Mehta MP, Khuntia D. Current strategies in whole-brain radiation therapy for brain metastases. Neurosurgery. 2005;57(5):S33–S44.
    1. Peacock KH, Lesser GJ. Current therapeutic approaches in patients with brain metastases. Current Treatment Options in Oncology. 2006;7(6):479–489.
    1. Tsao MN, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database of Systematic Reviews. 2006;3 Article ID CD003869.
    1. Gaspar L, Scott C, Rotman M, et al. Recursive Partitioning Analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. International Journal of Radiation Oncology Biology Physics. 1997;37(4):745–751.
    1. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. International Journal of Radiation Oncology Biology Physics. 1999;45(2):427–434.
    1. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. Journal of the American Medical Association. 1998;280(17):1485–1489.
    1. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–1672.
    1. Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. International Journal of Radiation Oncology Biology Physics. 2002;53(3):519–526.
    1. Roman DD, Sperduto PW. Neuropsychological effects of cranial radiation: current knowledge and future directions. International Journal of Radiation Oncology Biology Physics. 1995;31(4):983–998.
    1. DeAngelis LM, Delattre J-Y, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789–796.
    1. Li J, Bentzen SM, Li J, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. International Journal of Radiation Oncology Biology Physics. 2008;71(1):64–70.
    1. Welzel G, Fleckenstein K, Schaefer J, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. International Journal of Radiation Oncology Biology Physics. 2008;72(5):1311–1318.
    1. Paulino AC, Saw CB, Wen B-C. Comparison of posterior fossa and tumor bed boost in medulloblastoma. American Journal of Clinical Oncology. 2000;23(5):487–490.
    1. Palmer SL, Goloubeva O, Reddick WE, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. Journal of Clinical Oncology. 2001;19(8):2302–2308.
    1. Nandagopal R, Laverdière C, Mulrooney D, Hudson MM, Meacham L. Endocrine late effects of childhood cancer therapy: a report from the children’s oncology group. Hormone Research. 2008;69(2):65–74.
    1. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. Journal of Clinical Oncology. 2006;24(28):4570–4574.
    1. Lester JF, MacBeth FR, Coles B. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a cochrane review. International Journal of Radiation Oncology Biology Physics. 2005;63(3):690–694.
    1. Stuschke M, Eberhardt W, Pöttgen C, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. Journal of Clinical Oncology. 1999;17(9):2700–2709.
    1. Stuschke M, Pöttgen C. Prophylactic cranial irradiation as a component of intensified initial treatment of locally advanced non-small cell lung cancer. Lung Cancer. 2003;42(2):S53–S56.
    1. Pöttgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irradiation in operable stage IIIA non-small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. Journal of Clinical Oncology. 2007;25(31):4987–4992.
    1. Topkan E, Yildirim BA, Selek U, Yavuz MN. Cranial prophylactic irradiation in locally advanced non-small cell lung carcinoma: current status and future perspectives. Oncology. 2009;76(3):220–228.
    1. Gore E. RTOG 0214: a phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer. Clinical Advances in Hematology and Oncology. 2005;3(8):625–626.
    1. Movsas B, et al. Phase III study of prophylactic cranial irradeiation (PCI) vs. observation in patients with stage III nonsmall-cell lung cancer (NSCLC): neurocognitive and quality of life (QOL): analysis of RTOG 0214. ASTRO 2009; Abstract 2.
    1. Samson DJ, Seidenfeld J, Simon GR, et al. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) Chest. 2007;132(3):324S–339S.
    1. Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. The Lancet Oncology. 2009;10(5):467–474.
    1. Aupérin A, Arriagada R, Pignon J-P, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. New England Journal of Medicine. 1999;341(7):476–484.
    1. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. New England Journal of Medicine. 2007;357(7):664–672.
    1. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Journal of the National Cancer Institute. 1995;87(3):183–190.
    1. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms-results of an international phase III randomized controlled trial by the EORTC radiation oncology and lung cancer groups. Journal of Clinical Oncology. 2009;27(1):78–84.
    1. Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology. American Society of Hematology. Education Program. 2006:142–146.
    1. Sandlund JT, Pui C-H, Zhou Y, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009;23(6):1127–1130.
    1. Uyttebroeck A, Suciu S, Laureys G, et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. European Journal of Cancer. 2008;44(6):840–846.
    1. Merchant TE, Kiehna EN, Li C, et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. International Journal of Radiation Oncology Biology Physics. 2006;65(1):210–221.
    1. Cross NE, Glantz MJ. Neurologic complications of radiation therapy. Neurologic Clinics. 2003;21(1):249–277.
    1. Welzel T, Niethammer A, Mende U, et al. Diffusion tensor imaging screening of radiation-induced changes in the white matter after prophylactic cranial irradiation of patients with small cell lung cancer: first results of a prospective study. American Journal of Neuroradiology. 2008;29(2):379–383.
    1. Khong P-L, Kwong DLW, Chan GCF, Sham JST, Chan F-L, Ooi G-C. Diffusion-tensor imaging for the detection and quantification of treatment-induced white matter injury in children with medulloblastoma: a pilot study. American Journal of Neuroradiology. 2003;24(4):734–740.
    1. Bitzer M, Topka H. Progressive cerebral occlusive disease after radiation therapy. Stroke. 1995;26(1):131–136.
    1. Kondoh T, Morishita A, Kamei M, Okamura Y, Tamaki M, Kohmura E. Moyamoya syndrome after prophylactic cranial irradiation for acute lymphocytic leukemia. Pediatric Neurosurgery. 2003;39(5):264–269.
    1. Nishizawa S, Ryu H, Yokoyama T, et al. Post-irradiation vasculopathy of intracranial major arteries in children—report of two cases. Neurologia Medico-Chirurgica. 1991;31(6):336–341.
    1. Ishikawa N, Tajima C, Yofune N, Nishimura S, Kobayashi M. Moyamoya syndrome after cranial irradiation for bone marrow transplantation in a patient with acute leukemia. Neuropediatrics. 2006;37(6):364–366.
    1. Power DA. Late effects of radiotherapy: how to assess and improve outcomes. British Journal of Radiology. 2005;78(926):150–152.
    1. Hall EJ, Giaccia AJ, editors. Clinical Response of Normal Tissues, from Radiobiology for the Radiologist. 6th edition. chapter 19. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2006.
    1. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. International Journal of Radiation Oncology Biology Physics. 1991;21(1):109–122.
    1. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. British Journal of Radiology. 1989;62(740):679–694.
    1. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. International Journal of Radiation Oncology Biology Physics. 1980;6(1):1–9.
    1. Byrne TN. Cognitive sequelae of brain tumor treatment. Current Opinion in Neurology. 2005;18(6):662–666.
    1. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell cancer: results of a multicentre randomised trial. European Journal of Cancer. 1997;33(11):1752–1758.
    1. Ahles TA, Silberfarb PM, Herndon J, et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with and without warfarin: a study by the Cancer and Leukemia Group B. Journal of Clinical Oncology. 2006;24:1295–1304.
    1. Regine WF, Scott C, Murray K, Curran W. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. International Journal of Radiation Oncology Biology Physics. 2001;51(3):711–717.
    1. Komaki R, Meyers CA, Shin DM, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. International Journal of Radiation Oncology Biology Physics. 1995;33(1):179–182.
    1. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. Journal of Clinical Oncology. 2004;22(1):157–165.
    1. Welzel G, Fleckenstein K, Mai SK, Hermann B, Kraus-Tiefenbacher U, Wenz F. Acute neurocognitive impairment during cranial radiation therapy in patients with intracranial tumors. Strahlentherapie und Onkologie. 2008;184(12):647–654.
    1. Kanard A, Frytak S, Jatoi A. Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on management. Journal of Supportive Oncology. 2004;2(2):127–140.
    1. Baumann G, Fisher B, Schild S, et al. Clinical Radiation Oncology. 2nd edition. chapter 25. Philadelphia, Pa, USA: Churchill Livingstone; 2007. Meningioma, ependymoma, and other adult brain tumors; pp. 548–549, 554–556, 560–561.
    1. Jakacki RI. Treatment strategies for high-risk medulloblastoma and supratentorial primitive neuroectodermal tumors: review of the literature. Journal of Neurosurgery. 2005;102(1):44–52.
    1. Merchant TE, Wang M-H, Haida T, et al. Medulloblastoma: long-term results for patients treated with definitive radiation therapy during the computed tomography era. International Journal of Radiation Oncology Biology Physics. 1996;36(1):29–35.
    1. Halperin EC. Impact of radiation technique upon the outcome of treatment for medulloblastoma. International Journal of Radiation Oncology Biology Physics. 1996;36(1):233–239.
    1. Berger C, Thiesse P, Lellouch-Tubiana A, Kalifa C, Pierre-Kahn A, Bouffet E. Choroid plexus carcinomas in childhood: clinical features and prognostic factors. Neurosurgery. 1998;42(3):470–475.
    1. Thomas PRM, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. Journal of Clinical Oncology. 2000;18(16):3004–3011.
    1. Haas-Kogan DA, Missett BT, Wara WM, et al. Radiation therapy for intracranial germ cell tumors. International Journal of Radiation Oncology Biology Physics. 2003;56(2):511–518.
    1. Matsutani M. Pineal germ cell tumors. Progress in neurological surgery. 2009;23:76–85.
    1. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. New England Journal of Medicine. 1993;328(24):1725–1731.
    1. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. New England Journal of Medicine. 2005;352(10):978–986.
    1. Shim K-W, Kim T-G, Suh C-O, et al. Treatment failure in intracranial primary germinomas. Child’s Nervous System. 2007;23(10):1155–1161.
    1. Kun LE. Acute lymphoblastic leukemia. Seminars in Radiation Oncology. 1997;7(3):185–194.
    1. Pui C-H, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. The Lancet Oncology. 2008;9(3):257–268.
    1. Franklin JL, Finlay J. Leukemias and lymphomas: treatment and prophylaxis of the central nervous system. Current Treatment Options in Neurology. 2006;8(4):335–345.
    1. Trigg ME, Sather HN, Reaman GH, et al. Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Leukemia and Lymphoma. 2008;49(6):1142–1154.
    1. Waber DP, Shapiro BL, Carpentieri SC, et al. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer. 2001;92(1):15–22.
    1. LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. Journal of Clinical Oncology. 2002;20(1):237–246.
    1. Waber DP, Silverman LB, Catania L, et al. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. Journal of Clinical Oncology. 2004;22(13):2701–2707.
    1. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist. 2004;10(6):293–310.
    1. Schmiegelow M, Lassen S, Poulsen HS, et al. Cranial radiotherapy of childhood brain tumours: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study. Clinical Endocrinology. 2000;53(2):191–197.
    1. Douglas JG, Barker JL, Ellenbogen RG, Geyer JR. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. International Journal of Radiation Oncology Biology Physics. 2004;58(4):1161–1164.
    1. Merchant TE, Kiehna EN, Li C, Xiong X, Mulhern RK. Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. International Journal of Radiation Oncology Biology Physics. 2005;63(5):1546–1554.
    1. Merchant TE, Mulhern RK, Krasin MJ, et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. Journal of Clinical Oncology. 2004;22(15):3156–3162.
    1. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncology. 2004;5(7):399–408.
    1. Miralbell R, Bleher A, Huguenin P, et al. Pediatric medulloblastoma: radiation treatment technique and patterns of failure. International Journal of Radiation Oncology Biology Physics. 1997;37(3):523–529.
    1. Paulino AC, Narayana A, Mohideen MN, Jeswani S. Posterior fossa boost in medulloblastoma: an analysis of dose to surrounding structures using 3-dimensional (conformal) radiotherapy. International Journal of Radiation Oncology Biology Physics. 2000;46(2):281–286.
    1. Merchant TE, Kun LE, Krasin MJ, et al. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. International Journal of Radiation Oncology Biology Physics. 2008;70(3):782–787.
    1. Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. International Journal of Radiation Oncology Biology Physics. 2002;52(3):599–605.
    1. Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? International Journal of Radiation Oncology Biology Physics. 2005;63(2):362–372.
    1. Yuh GE, Loredo LN, Yonemoto LT, et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer Journal. 2004;10(6):386–390.
    1. St. Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. International Journal of Radiation Oncology Biology Physics. 2004;58(3):727–734.
    1. Pui C-H, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. New England Journal of Medicine. 2009;360(26):2730–2741.
    1. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. International Journal of Radiation Oncology Biology Physics. 1992;23(1):9–17.
    1. Bessell EM, López-Guillermo A, Villá S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. Journal of Clinical Oncology. 2002;20(1):231–236.
    1. O’Brien P, Roos D, Pratt G, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. Journal of Clinical Oncology. 2000;18(3):519–526.
    1. Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group protocol 88-06. Journal of Clinical Oncology. 1996;14(2):556–564.
    1. DeAngelis LM, Seiferheld W, Clifford Schold S, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10. Journal of Clinical Oncology. 2002;20(24):4643–4648.
    1. Fisher B, Seiferheld W, Schultz C, et al. Secondary analysis of radiation therapy oncology group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. Journal of Neuro-Oncology. 2005;74(2):201–205.
    1. Poortmans PMP, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. Journal of Clinical Oncology. 2003;21(24):4483–4488.
    1. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. Journal of Clinical Oncology. 2000;18(17):3144–3150.
    1. Pels H, Schmidt-Wolf IGH, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. Journal of Clinical Oncology. 2003;21(24):4489–4495.
    1. Batchelor T, Carson K, O’Neill A, et al. Treatment of pimary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. Journal of Clinical Oncology. 2003;21(6):1044–1049.
    1. Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Journal of Clinical Oncology. 2003;21(14):2726–2731.
    1. Omuro AMP, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Archives of Neurology. 2005;62(10):1595–1600.
    1. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology. 2004;62(3):451–456.
    1. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the memorial sloan-kettering cancer center prognostic model. Journal of Clinical Oncology. 2006;24(36):5711–5715.
    1. Ferreri AJM, Blay J-Y, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. Journal of Clinical Oncology. 2003;21(2):266–272.
    1. Aoyama H, Tago M, Kato N, et al. Neurocognitive Function of Patients with Brain Metastasis Who Received Either Whole Brain Radiotherapy Plus Stereotactic Radiosurgery or Radiosurgery Alone. International Journal of Radiation Oncology Biology Physics. 2007;68(5):1388–1395.
    1. Chang EL, Wefel JS, Maor MH, et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 2007;60(2):277–283.
    1. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. Journal of the American Medical Association. 2006;295(21):2483–2491.
    1. Sawrie SM, Guthrie BL, Spencer SA, et al. Predictors of Distant Brain Recurrence for Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery Alone. International Journal of Radiation Oncology Biology Physics. 2008;70(1):181–186.
    1. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD. Stereotactic radiosurgery for four or more intracranial metastases. International Journal of Radiation Oncology Biology Physics. 2006;64(3):898–903.
    1. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. International Journal of Radiation Oncology Biology Physics. 1999;45(2):427–434.
    1. Pirzkall A, Debus J, Lohr F, et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. Journal of Clinical Oncology. 1998;16(11):3563–3569.
    1. Rades D, Kueter J-D, Hornung D, et al. Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT + SRS) for one to three brain metastases. Strahlentherapie und Onkologie. 2008;184(12):655–662.
    1. Shehata MK, Young B, Reid B, et al. Stereotatic radiosurgery of 468 brain metastases ≤2 cm: implications for SRS dose and whole brain radiation therapy. International Journal of Radiation Oncology Biology Physics. 2004;59(1):87–93.
    1. Varlotto JM, Flickinger JC, Niranjan A, Bhatnagar A, Kondziolka D, Lunsford LD. The impact of whole-brain radiation therapy on the long-term control and morbidity of patients surviving more than one year after gamma knife radiosurgery for brain metastases. International Journal of Radiation Oncology Biology Physics. 2005;62(4):1125–1132.
    1. Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD. Radiosurgery with or without whole-brain radiotherapy for brain metastases: the patients’ perspective regarding complications. American Journal of Clinical Oncology. 2005;28(2):173–179.
    1. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. The Lancet Oncology. 2009;10(11):1037–1044.
    1. Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. Journal of Clinical Oncology. 2007;25(10):1260–1266.
    1. Corn BW, Moughan J, Knisely JPS, et al. Prospective Evaluation of Quality of Life and Neurocognitive Effects in Patients With Multiple Brain Metastases Receiving Whole-Brain Radiotherapy With or Without Thalidomide on Radiation Therapy Oncology Group (RTOG) Trial 0118. International Journal of Radiation Oncology Biology Physics. 2008;71(1):71–78.
    1. Nieder C, Leicht A, Motaref B, Nestle U, Niewald M, Schnabel K. Late radiation toxicity after whole-brain radiotherapy: the influence of antiepileptic drugs. American Journal of Clinical Oncology. 1999;22(6):573–579.
    1. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma? A prologue. Cancer. 2004;101(3):466–475.
    1. Regine WF, Schmitt FA, Scott CB, et al. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. International Journal of Radiation Oncology Biology Physics. 2004;58(5):1346–1352.
    1. Ghia A, Tomé WA, Thomas S, et al. Distribution of brain metastases in relation to the hippocampus: implications for neurocognitive functional preservation. International Journal of Radiation Oncology Biology Physics. 2007;68(4):971–977.
    1. Gutiérrez AN, Westerly DC, Tomé WA, et al. Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. International Journal of Radiation Oncology Biology Physics. 2007;69(2):589–597.
    1. Marsh JC, Herskovic AM, Gielda BT, et al. Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients. International Journal of Radiation Oncology Biology Physics. 2010;76(2):504–512.
    1. Kier EL, Kim JH, Fulbright RK, Bronen RA. Embryology of the human fetal hippocampus: Mr imaging, anatomy, and histology. American Journal of Neuroradiology. 1997;18(3):525–532.
    1. Lautin A. The Limbic Brain. New York, NY, USA: Kluwer Academic/ Plenum; 2001.
    1. Eriksson PS, Perfilieva E, Björk-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nature Medicine. 1998;4(11):1313–1317.
    1. Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nature Medicine. 2002;8(9):955–962.
    1. Monje ML, Palmer T. Radiation injury and neurogenesis. Current Opinion in Neurology. 2003;16(2):129–134.
    1. Abayomi OK. Pathogenesis of irradiation-induced cognitive dysfunction. Acta Oncologica. 1996;35(6):659–663.
    1. Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD, Fike JR. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Research. 2003;63(14):4021–4027.
    1. Marsh J, Gielda B, Herskovic A, et al. Sparing of the limbic circuit and pituitary during whole brain radiation therapy: a dosimetric study using helical tomotherapy. submitted for publication.
    1. Hsu F, Carolan H, Nichol A, et al. Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1–3 brain metastases: a feasibility study using volumetric modulated Arc therapy. International Journal of Radiation Oncology Biology Physics. 2010;76(5):1480–1485.
    1. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992;255(5052):1707–1710.
    1. Taupin P, Gage FH. Adult neurogenesis and neural stem cells of the central nervous system in mammals. Journal of Neuroscience Research. 2002;69(6):745–749.
    1. Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell. 1999;97(6):703–716.
    1. Morshead CM, Reynolds BA, Craig CG, et al. Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. Neuron. 1994;13(5):1071–1082.
    1. Becker S. A computational principle for hippocampal learning and neurogenesis. Hippocampus. 2005;15(6):722–738.
    1. Wiskott L, Rasch MJ, Kempermann G. A functional hypothesis for adult hippocampal neurogenesis: avoidance of catastrophic interference in the dentate gyrus. Hippocampus. 2006;16(3):329–343.
    1. Aimone JB, Wiles J, Gage FH. Potential role for adult neurogenesis in the encoding of time in new memories. Nature Neuroscience. 2006;9(6):723–727.
    1. Arias-Carrión O, Freundlieb N, Oertel WH, Höglinger GU. Adult neurogenesis and Parkinson’s disease. CNS and Neurological Disorders—Drug Targets. 2007;6(5):326–335.
    1. Fallon J, Reid S, Kinyamu R, et al. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(26):14686–14691.
    1. Arias-Carrión O, Verdugo-Díaz L, Feria-Velasco A, et al. Neurogenesis in the subventricular zone following transcranial magnetic field stimulation and nigrostriatal lesions. Journal of Neuroscience Research. 2004;78(1):16–28.
    1. Arias-Carrión O, Hernández-López S, Ibañez-Sandoval O, Bargas J, Hernández-Cruz A, Drucker-Colín R. Neuronal precursors within the adult rat subventricular zone differentiate into dopaminergic neurons after substantia nigra lesion and chromaffin cell transplant. Journal of Neuroscience Research. 2006;84(7):1425–1437.
    1. Höglinger GU, Rizk P, Muriel MP, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nature Neuroscience. 2004;7(7):726–735.
    1. Barani IJ, Cuttino LW, Benedict SH, et al. Neural stem cell-preserving external-beam radiotherapy of central nervous system malignancies. International Journal of Radiation Oncology Biology Physics. 2007;68(4):978–985.
    1. Barani IJ, Benedict SH, Lin P-S. Neural stem cells: implications for the conventional radiotherapy of central nervous system malignancies. International Journal of Radiation Oncology Biology Physics. 2007;68(2):324–333.
    1. Fike JR, Rosi S, Limoli CL. Neural precursor cells and central nervous system radiation sensitivity. Seminars in Radiation Oncology. 2009;19(2):122–132.
    1. Winocur G, Wojtowicz JM, Sekeres M, Snyder JS, Wang S. Inhibition of neurogenesis interferes with hippocampus-dependent memory function. Hippocampus. 2006;16(3):296–304.
    1. Rola R, Raber J, Rizk A, et al. Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Experimental Neurology. 2004;188(2):316–330.
    1. Raber J, Fan Y, Matsumori Y, et al. Irradiation attenuates neurogenesis and exacerbates ischemia-induced deficits. Annals of Neurology. 2004;55(3):381–389.
    1. Raber J, Rola R, LeFevour A, et al. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiation Research. 2004;162(1):39–47.
    1. Madsen TM, Kristjansen PEG, Bolwig TG, Wörtwein G. Arrested neuronal proliferation and impaired hippocampal function following fractionated brain irradiation in the adult rat. Neuroscience. 2003;119(3):635–642.
    1. Gage FH. Mammalian neural stem cells. Science. 2000;287(5457):1433–1438.
    1. Monje ML, Vogel H, Masek M, Ligon KL, Fisher PG, Palmer TD. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Annals of Neurology. 2007;62(5):515–520.
    1. Marsh JC, Godbole RH, Herskovic AM, et al. Sparing of the neural stem cell compartment during whole brain radiation therapy: a dosimetric study using helical tomotherapy
    1. Herskovic AM, Han D, Marsh J, et al. Cognitive Sparing during Elective Brain Radiation: A Prospective Phase II Trial of Prophylactic Cranial Irradiation (PCI) for Limited Stage Small Cell Lung Cancer and Whole Brain Radiotherapy (WBRT) for Solitary Resected Brain Metastases With Selective Dosimetric Sparing of the Pituitary and Bilateral Hippocampus and Limbic Circuit Using Helical Tomotherapy. Currently open at Rush University Medical Center, Chicago, Ill, USA.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する